AI-based solutions to help clinicians screen for different cardiac pathologies.
About Us
Bioquantis provides screening solutions for various cardiac pathologies to clinicians. Our tool is an AI-based solution available to cardiologists.
Born out of academic research, Bioquantis leverages its experience in clinical research and the power of artificial intelligence to develop tools for predicting and aiding in the diagnosis of heart diseases.
Initially focusing on epidemiological analysis of coronary artery disease, Bioquantis now offers practical clinical solutions, including software for aiding in the ultrasound screening of cardiac amyloidosis (ATTR).
Our Solutions
Clinical cardiologists
Bioquantis offers solutions to clinical cardiologists to: Assist in diagnosing heart diseases using our software coupled with cardiac ultrasound, stratify patient risk in primary and secondary prevention.
Clinical research
Bioquantis also aims to collaborate with various stakeholders in clinical research (academic, industrial, and hospitals) to assist in the design, execution, and analysis of clinical studies.
Publications in Clinical Epidemiology
Darmon A, Sorbets E, Ducrocq G, ELBEZ Y, Abtan J, Popovic B, Ohman EM, Röther J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG; REACH Registry Investigators.
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. J Am Coll Cardiol. 2019;73:3281-3291. doi: 10.1016/j.jacc.2019.04.046. PMID: 31248549.
Darmon A, Bhatt DL, ELBEZ Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG.
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018;39:750-757a. doi: 10.1093/eurheartj/ehx658. PMID: 29186454.
Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. Eur Heart J. 2018;39:3855-3863. doi: 10.1093/eurheartj/ehy488. PMID: 30124796; PMCID: PMC6234847.
Vidal-Petiot E, Sorbets E, Bhatt DL, Ducrocq G, ELBEZ Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG.
Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack C Jr, Wiviott SD, ELBEZ Y, Sabatine MS, Steg PG.
Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Circulation. 2017;136:1895-1907. doi: 10.1161/CIRCULATIONAHA.117.029779. PMID: 28893843.
Our Team
Bioquantis brings together experts in cardiology and data science with a common mission: to anticipate diagnosis and improve patient health.
Our tool is an AI-based solution available to cardiologists. Our team is naturally multidisciplinary, comprising specialists in cardiology, statistics, artificial intelligence, medical affairs, and entrepreneurship.
The founders have over 15 years of experience in clinical research, resulting in over 1000 referenced publications in cardiology.
Leadership Team
Advisory board
Our Partnerships
Bioquantis has partnered with Assistance Publique-Hôpitaux de Paris, the network of university hospitals in the Greater Paris region, providing care to approximately 8 million patients in 38 hospitals.
Bioquantis partnered with Pfizer in 2022 to accelerate the development of a screening solution for cardiac amyloidosis (aTTR).
Bioquantis has partnered with Banque Publique d'Investissement in 2024.
Contact
Bioquantis
INSERM U_1148/LVTS Building,
Bichat Hospital, 46 rue Henri Huchard,
75018 Paris, France
contact@bioquantis.fr